• Private Equity Firm

    Shavit Capital is an investment firm that specializes in late-stage investments in Israeli and Israeli-related companies.

    Shavit Capital has over $400 million under management across five separate private equity funds. Shavit Capital was founded in 2008 and the fifth fund was raised in 2019.  The Funds invest in Israeli companies with proven technologies, products, markets and strong management teams. The Funds invest in equity mezzanine or bridge rounds in companies which subsequently expect to raise relatively larger amounts pursuant to an IPO on a major international public exchange or a dual listing of a company that trades on the Tel Aviv Stock Exchange.

    Shavit Capital also invests in other late-stage opportunities, especially through PIPEs (Private Investment in Public Equites) of Israeli publicly-traded companies.

  • Company News

    Ayala Pharmaceuticals Announces $25 Million Strategic Financing
    February 19, 2021
    PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial o
    February 16, 2021
    Gamida Cell raises $75m in convertible notes
    February 16, 2021
    Hope grows for blood cancer patients, as cell therapy firm’s key trial succ
    February 11, 2021
    Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clini
    January 28, 2021
    Trax plans New York IPO at $2b valuation, Israel layoffs
    January 20, 2021
    Alpha Tau Medical Announces Appointment of Peter Melnyk as New Board Member
    January 12, 2021
    PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cance
    December 22, 2020
    Gamida Cell Announces Closing of $75 Million Public Offering, Including Full
    December 21, 2020
    Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
    December 21, 2020